Mesoblast Ltd
MESO15.370USD
+1.050+7.33%
Close 11/21, 16:00（ET）Quotes delayed by 15 min
1.97BMarket Cap
LossP/E TTM
More Details of Mesoblast Ltd Company
Mesoblast Limited is an Australia-based company, which is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. It has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of late-stage product candidates. It is developing product candidates for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Remestemcel-L is being developed for inflammatory diseases in children and adults including steroid refractory acute graft versus host disease, and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for advanced chronic heart failure (REVASCOR) and chronic low back pain (MPC-06-ID). Two products have been commercialized in Japan and Europe by the Company's licensees. It has established commercial partnerships in Europe and China for certain Phase III assets.
Mesoblast Ltd Info
Ticker SymbolMESO
Company nameMesoblast Ltd
IPO dateDec 16, 2004
CEODr. Silviu Itescu
Number of employees73
Security typeDepository Receipt
Fiscal year-endDec 16
AddressL 38 55 Collins St
CityMELBOURNE
Stock exchangeNASDAQ Global Select Consolidated
CountryAustralia
Postal code3000
Phone61396396036
Websitehttps://www.mesoblast.com/
Ticker SymbolMESO
IPO dateDec 16, 2004
CEODr. Silviu Itescu
Company Executives of Mesoblast Ltd
Name
Name/Position
Position
Shareholding
Change
Dr. Eric A. Rose, M.D.
Dr. Eric A. Rose, M.D.
Executive Director, Chief Medical Officer
Executive Director, Chief Medical Officer
71.47K
+73.64%
Dr. Fiona See, Ph.D.
Dr. Fiona See, Ph.D.
Senior Vice President, Head - Translational Research
Senior Vice President, Head - Translational Research
--
--
Mr. William M. (Bill) Burns
Mr. William M. (Bill) Burns
Non-Executive Independent Vice Chairman of the Board
Non-Executive Independent Vice Chairman of the Board
--
--
Mr. Philip R. Krause, M.D.
Mr. Philip R. Krause, M.D.
Non-Executive Non-Independent Director
Non-Executive Non-Independent Director
--
--
Mr. Paul Hughes
Mr. Paul Hughes
Joint Company Secretary
Joint Company Secretary
--
--
Dr. Fiona See, Ph.D.
Dr. Fiona See, Ph.D.
Senior Vice President, Head - Translational Research
Senior Vice President, Head - Translational Research
--
--
Mr. Philip J. (Phil) Facchina
Mr. Philip J. (Phil) Facchina
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Niva Sivakumar
Ms. Niva Sivakumar
Joint Company Secretary
Joint Company Secretary
--
--
Mr. Paul Hughes
Mr. Paul Hughes
Joint Company Secretary
Joint Company Secretary
--
--
Ms. Niva Sivakumar
Ms. Niva Sivakumar
Joint Company Secretary
Joint Company Secretary
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Eric A. Rose, M.D.
Dr. Eric A. Rose, M.D.
Executive Director, Chief Medical Officer
Executive Director, Chief Medical Officer
71.47K
+73.64%
Dr. Fiona See, Ph.D.
Dr. Fiona See, Ph.D.
Senior Vice President, Head - Translational Research
Senior Vice President, Head - Translational Research
--
--
Mr. William M. (Bill) Burns
Mr. William M. (Bill) Burns
Non-Executive Independent Vice Chairman of the Board
Non-Executive Independent Vice Chairman of the Board
--
--
Mr. Philip R. Krause, M.D.
Mr. Philip R. Krause, M.D.
Non-Executive Non-Independent Director
Non-Executive Non-Independent Director
--
--
Mr. Paul Hughes
Mr. Paul Hughes
Joint Company Secretary
Joint Company Secretary
--
--
Dr. Fiona See, Ph.D.
Dr. Fiona See, Ph.D.
Senior Vice President, Head - Translational Research
Senior Vice President, Head - Translational Research
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Gueck (William J)
5.00%
Legal & General Investment Management Ltd.
0.51%
Morgan Stanley & Co. International Plc
0.32%
Goldman Sachs & Company, Inc.
0.32%
BlackRock Institutional Trust Company, N.A.
0.29%
Other
93.56%
Shareholders
Shareholders
Proportion
Gueck (William J)
5.00%
Legal & General Investment Management Ltd.
0.51%
Morgan Stanley & Co. International Plc
0.32%
Goldman Sachs & Company, Inc.
0.32%
BlackRock Institutional Trust Company, N.A.
0.29%
Other
93.56%
Shareholder Types
Shareholders
Proportion
Individual Investor
5.09%
Investment Advisor
1.52%
Research Firm
0.84%
Investment Advisor/Hedge Fund
0.68%
Bank and Trust
0.03%
Hedge Fund
0.02%
Venture Capital
0.01%
Other
91.81%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
134
3.48M
2.71%
-1.10M
2025Q2
126
4.04M
3.16%
+542.30K
2025Q1
132
4.07M
3.19%
+9.28K
2024Q4
122
3.23M
2.55%
+620.09K
2024Q3
100
1.76M
1.52%
-1.23M
2024Q2
98
1.70M
1.52%
-705.91K
2024Q1
97
1.24M
1.12%
-806.95K
2023Q4
94
840.17K
0.85%
-1.02M
2023Q3
97
766.21K
0.94%
-1.35M
2023Q2
99
982.29K
1.21%
-1.15M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Gueck (William J)
6.42M
5.01%
+6.42M
--
Sep 12, 2025
Morgan Stanley & Co. International Plc
313.52K
0.24%
--
--
Jun 30, 2025
Goldman Sachs & Company, Inc.
415.46K
0.32%
+158.32K
+61.57%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
499.00K
0.39%
-66.89K
-11.82%
Jun 30, 2025
Susquehanna International Group, LLP
234.59K
0.18%
-26.35K
-10.10%
Jun 30, 2025
Summit Wealth Strategies
199.29K
0.16%
+1.13K
+0.57%
Jun 30, 2025
UBS Financial Services, Inc.
160.04K
0.12%
+22.70K
+16.53%
Jun 30, 2025
Aperio Group, LLC
135.17K
0.11%
+2.68K
+2.02%
Jun 30, 2025
View more
Related ETFs
Updated: Thu, Nov 6
Updated: Thu, Nov 6
Name
Proportion
iShares Biotechnology ETF
0.1%
Invesco Nasdaq Biotechnology ETF
0.08%
ProShares Ultra Nasdaq Biotechnology
0.08%
ActivePassive International Equity ETF
0.01%
iShares Biotechnology ETF
Proportion0.1%
Invesco Nasdaq Biotechnology ETF
Proportion0.08%
ProShares Ultra Nasdaq Biotechnology
Proportion0.08%
ActivePassive International Equity ETF
Proportion0.01%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Dec 22, 2023
Merger
2→1
Dec 22, 2023
Merger
2→1
Dec 22, 2023
Merger
2→1
Dec 22, 2023
Merger
2→1
Date
Type
Ratio
Dec 22, 2023
Merger
2→1
Dec 22, 2023
Merger
2→1
Dec 22, 2023
Merger
2→1
Dec 22, 2023
Merger
2→1
FAQs
Who are the top five shareholders of Mesoblast Ltd?
The top five shareholders of Mesoblast Ltd are:
Gueck (William J) holds 6.42M shares, accounting for 5.01% of the total shares.
Morgan Stanley & Co. International Plc holds 313.52K shares, accounting for 0.24% of the total shares.
Goldman Sachs & Company, Inc. holds 415.46K shares, accounting for 0.32% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 499.00K shares, accounting for 0.39% of the total shares.
Susquehanna International Group, LLP holds 234.59K shares, accounting for 0.18% of the total shares.
Gueck (William J) holds 6.42M shares, accounting for 5.01% of the total shares.
Morgan Stanley & Co. International Plc holds 313.52K shares, accounting for 0.24% of the total shares.
Goldman Sachs & Company, Inc. holds 415.46K shares, accounting for 0.32% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 499.00K shares, accounting for 0.39% of the total shares.
Susquehanna International Group, LLP holds 234.59K shares, accounting for 0.18% of the total shares.
What are the top three shareholder types of Mesoblast Ltd?
The top three shareholder types of Mesoblast Ltd are:
Gueck (William J)
Legal & General Investment Management Ltd.
Morgan Stanley & Co. International Plc
Gueck (William J)
Legal & General Investment Management Ltd.
Morgan Stanley & Co. International Plc
How many institutions hold shares of Mesoblast Ltd (MESO)?
As of 2025Q3, 134 institutions hold shares of Mesoblast Ltd, with a combined market value of approximately 3.48M, accounting for 2.71% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -0.45%.
What is the biggest source of revenue for Mesoblast Ltd?
In --, the -- business generated the highest revenue for Mesoblast Ltd, amounting to -- and accounting for --% of total revenue.
